Robert Forbes Burns
Director/Board Member bei CIRCIO HOLDING ASA
Profil
Dr. Robert F.
Burns is an Independent Director at Circio Holding ASA and a Chairman at Affibody Medical AB.
He is on the Board of Directors at Circio Holding ASA. Dr. Burns was previously employed as a President & Chief Executive Officer by Affitech A/S, a Chairman by Haemostatix Ltd., a President & Chief Executive Officer by Celldex Therapeutics, Inc. (Old), a Chief Executive Officer by 4-Antibody AG, a Principal by ABT Corp, a Principal by Applied Biotech, Inc., a Chief Executive Officer by Celldex Therapeutics, Inc., a Principal by Ligand UK Ltd., a Director-Technology Licensing by Ludwig Institute for Cancer Research Ltd., a Principal by Ogs SA, a Principal by Oxford GlycoSciences Plc, and a Principal by Piramed Ltd.
He also served on the board at Targovax Oy.
He received his doctorate degree from the University of Birmingham.
Aktive Positionen von Robert Forbes Burns
| Unternehmen | Position | Beginn |
|---|---|---|
| CIRCIO HOLDING ASA | Director/Board Member | 01.07.2015 |
Affibody Medical AB
 Affibody Medical AB Pharmaceuticals: MajorHealth Technology Affibody Medical AB provides biopharmaceuticals services. It develops Affibody, an antibody mimetic and Albumod, a technology that enhances the efficacy of biopharmaceuticals by extending their circulatory half-life through a strong binding to albumin. The company was founded by Karin Nord and Carl Erik Mathias Uhlén in 1998 and is headquartered in Stockholm, Sweden. | Chairman | - |
Ehemalige bekannte Positionen von Robert Forbes Burns
| Unternehmen | Position | Ende |
|---|---|---|
Celldex Therapeutics, Inc. (Old)
 Celldex Therapeutics, Inc. (Old) BiotechnologyHealth Technology Celldex Therapeutics, Inc. discovers, develops and commercialized novel immunotherapeutics. It offers treatment for cancer, infectious diseased and immune system disorders. The company was founded in May, 2003 and is headquartered in Philipsburg, NJ. | Chief Executive Officer | 01.10.2008 |
Targovax Oy
 Targovax Oy Pharmaceuticals: MajorHealth Technology Targovax Oy focuses on the development and commercialization of targeted cancer immunotherapy. It is a biotechnology company with novel immunotherapy platform that is based on engineered oncolytic viruses armed with potent immune-stimulating transgenes. The firm's products induce a tailored response by the immune system directed at each patient’s unique cancer cells. The company was founded by Pekka Ilmari Simula and Antti Vuolanto in 2009 and is headquartered in Helsinki, Finland. | Director/Board Member | - |
4-Antibody AG
 4-Antibody AG Pharmaceuticals: MajorHealth Technology 4-Antibody AG was discovers and develops drugs. The company was founded in 2002 and headquartered in Basel, Switzerland. | Chief Executive Officer | - |
Affitech A/S
 Affitech A/S Pharmaceuticals: MajorHealth Technology Affitech A/S engages in the development of human antibody therapeutics. It focuses on human antibodies for cancer such as hematological and solid tumors; and serious inflammatory conditions including rheumatoid arthritis and severe asthma. The firm enters into partnerships and collaborations with biotechnology companies for antibody discovery and development. The company was founded by Søren Mouritsen and Henrik Irgang Elsner on October 1, 1990 and is headquartered in Copenhagen, Denmark. | Chief Executive Officer | - |
| Applied Biotech, Inc. | Corporate Officer/Principal | - |
Ausbildung von Robert Forbes Burns
| University of Birmingham | Doctorate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 2 |
|---|---|
| CELLDEX THERAPEUTICS, INC. | Health Services |
| CIRCIO HOLDING ASA | Health Technology |
| Private Unternehmen | 13 |
|---|---|
Ligand UK Ltd.
 Ligand UK Ltd. Pharmaceuticals: MajorHealth Technology Ligand UK Ltd. is a commercial stage pharmaceutical company. Its products include Tuzistra XR, targeting the U.S. prescription cough-cold market, Moxatag, a once-a-day formulation of the antibiotic and amoxicillin, and frovatriptan, used for the acute treatment of migraine. It also develops and commercializes multiple novel products focused on the U.S. prescription cough-cold market. The company was founded by Keith G. McCullagh and Andre L. Lamotte in 1986 and is headquartered in Winnersh, the United Kingdom. | Health Technology |
| Applied Biotech, Inc. | Health Technology |
Celldex Therapeutics, Inc. (Old)
Celldex Therapeutics, Inc. (Old) BiotechnologyHealth Technology Celldex Therapeutics, Inc. discovers, develops and commercialized novel immunotherapeutics. It offers treatment for cancer, infectious diseased and immune system disorders. The company was founded in May, 2003 and is headquartered in Philipsburg, NJ. | Health Technology |
Piramed Ltd.
 Piramed Ltd. Miscellaneous Commercial ServicesCommercial Services PIramed Ltd. develops drugs, diagnostics, and other therapeutic products. It develops treatment for cancers which include proliferation, invasion, angiogenesis, and metastasis. The company was co-founded by Michael Waterfield, Peter Parker, and Paul Workman in 2003 and is headquartered in Slough, UK. | Commercial Services |
Affibody Medical AB
Affibody Medical AB Pharmaceuticals: MajorHealth Technology Affibody Medical AB provides biopharmaceuticals services. It develops Affibody, an antibody mimetic and Albumod, a technology that enhances the efficacy of biopharmaceuticals by extending their circulatory half-life through a strong binding to albumin. The company was founded by Karin Nord and Carl Erik Mathias Uhlén in 1998 and is headquartered in Stockholm, Sweden. | Health Technology |
Ogs SA
 Ogs SA Engineering & ConstructionIndustrial Services Ogs SA is a French company that manufactures electrical products. | Industrial Services |
Oxford GlycoSciences Plc
 Oxford GlycoSciences Plc Pharmaceuticals: MajorHealth Technology Oxford Glycosciences Plc provides biopharmaceutical products. The company develops and manufactures novel products for the diagnosis and treatment of human disease. Its products include bayer, pioneer hi-breddupont, medarex, genmab, glaxosmithkline, neogenesis and pfizer. It was founded in 1988. The company is headquartered in Abingdon, UK. | Health Technology |
| ABT Corp | Technology Services |
4-Antibody AG
4-Antibody AG Pharmaceuticals: MajorHealth Technology 4-Antibody AG was discovers and develops drugs. The company was founded in 2002 and headquartered in Basel, Switzerland. | Health Technology |
Haemostatix Ltd.
 Haemostatix Ltd. Pharmaceuticals: MajorHealth Technology Haemostatix Ltd. designs and develops solutions for haemostasis and thrombosis. Its products include Rapid and effective haemostatic action which is new class of topical coagulant or haemostat that is applied directly to a wound during surgery to control bleeding, and ready-to-use formulations, blood-free ingredients and a new class with a unique mode of action. The company was founded by Sarah Middleton and Alison Goodall in 2003 and is headquartered in Nottingham, the United Kingdom. | Health Technology |
Ludwig Institute for Cancer Research Ltd.
 Ludwig Institute for Cancer Research Ltd. Medical/Nursing ServicesHealth Services Ludwig Institute For Cancer Research Ltd. is non-profit organization engages in the prevention and control of cancer through researches, integrated laboratory and clinical trials. The firm operates in the areas of cell biology, genomics, immunology, neuroscience, signaling, stem cells, therapeutic, tumor biology, brain and breast cancer, immunotherapy, and melanoma. The company was founded by Daniel K. Ludwig in 1971 and is headquartered in New York, NY. | Health Services |
Affitech A/S
Affitech A/S Pharmaceuticals: MajorHealth Technology Affitech A/S engages in the development of human antibody therapeutics. It focuses on human antibodies for cancer such as hematological and solid tumors; and serious inflammatory conditions including rheumatoid arthritis and severe asthma. The firm enters into partnerships and collaborations with biotechnology companies for antibody discovery and development. The company was founded by Søren Mouritsen and Henrik Irgang Elsner on October 1, 1990 and is headquartered in Copenhagen, Denmark. | Health Technology |
Targovax Oy
Targovax Oy Pharmaceuticals: MajorHealth Technology Targovax Oy focuses on the development and commercialization of targeted cancer immunotherapy. It is a biotechnology company with novel immunotherapy platform that is based on engineered oncolytic viruses armed with potent immune-stimulating transgenes. The firm's products induce a tailored response by the immune system directed at each patient’s unique cancer cells. The company was founded by Pekka Ilmari Simula and Antti Vuolanto in 2009 and is headquartered in Helsinki, Finland. | Health Technology |
